Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Alternative Options For Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, And Ketamine: A Narrative Review Of Clinical Evidence, Amber N. Edinoff, Juliana M. Fort, Christina Singh, Sarah E. Wagner, Jessica R. Rodriguez, Catherine A. Johnson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
Alternative Options For Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, And Ketamine: A Narrative Review Of Clinical Evidence, Amber N. Edinoff, Juliana M. Fort, Christina Singh, Sarah E. Wagner, Jessica R. Rodriguez, Catherine A. Johnson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate nociceptive signals and have been studied for chronic pain treatment. Psilocybin, commonly known as "magic mushrooms", works at the serotonin receptor, 5-HT. Psilocybin has been found in current studies to help with migraines since it has a tryptamine structure and works similarly to triptans. Psilocybin …
Historical Pathways For Opioid Addiction, Withdrawal With Traditional And Alternative Treatment Options With Ketamine, Cannabinoids, And Noribogaine: A Narrative Review, Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
Historical Pathways For Opioid Addiction, Withdrawal With Traditional And Alternative Treatment Options With Ketamine, Cannabinoids, And Noribogaine: A Narrative Review, Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist naltrexone, the partial-agonist buprenorphine, and the full agonist methadone. Naloxone is an antagonist used to rapidly reverse opioid overdose. While these treatments are well-established and used regularly, the gravity of the opioid epidemic necessitates that all possible avenues …